Science Corporation Implants PRIMA Chip in First Stargardt Patient

What changed

Science Corporation has implanted its vision-restoring PRIMA chip in its first patient with Stargardt disease, the company says. Max Hodak, Science Corporation’s co-founder and former Neuralink president, described the work at TechCrunch Disrupt as part of a path toward a novel brain-computer interface.

Why it matters

This is an important step because PRIMA has moved from an engineering project to an implanted device in a person with Stargardt disease. But the headline has a sharp limit: no patient outcome, trial status, regulatory status, device performance or implantation date was provided.

The bigger idea is the bridge Science Corporation is trying to build. A chip intended to restore vision is also being positioned as groundwork for a new kind of brain-computer interface. That makes the implantation more than a medical milestone for the company; it is an early test of whether its hardware can operate inside the human body while supporting a much broader computing ambition.

For now, the meaningful question is simple: what happens next with the patient and the device? Those results will matter more than the implantation announcement itself.